Leading Spanish companies in cancer research

This center stands out for its reference model in translating precision oncology into clinical practice. Its focus on integrating the most advanced research directly into patient treatment makes it a fundamental player.

The CNIO is the leading cancer research center in Spain and one of the most important internationally. Its focus on basic, translational, and clinical research keeps it at the forefront in the search for improvements in cancer prevention, diagnosis, and treatment.

The IOB is a leader in oncology, diagnosis, and treatment, with an oncological clinical trials unit. Its focus on research and precision oncology, together with its clinical centers, contributes significantly to advancements in cancer treatment.

Lifesome Therapeutics leads the development of advanced nanotechnology tools for cancer treatment. Its 'Ohmline' nanoparticle promises controlled drug release, improving efficacy and reducing toxicity in hard-to-reach tumors.

Nuage Therapeutics stands out for its innovative approach to intrinsically disordered proteins (IDRs), which represent a great challenge in biomedicine. Its research seeks new therapeutic opportunities for traditionally resistant or hard-to-access tumors.

KeyZell is a pioneering biotechnology company that combines the development of a new generation of cancer drugs with an innovative artificial intelligence system. This dual approach positions it as key in oncological precision medicine.

This institute is an international reference center for hematological cancers and cell and gene therapies. Its leadership in the research of leukemias and other blood cancers keeps it at the forefront of the field.

The IQAC-CSIC has numerous active cancer research projects, from molecular design to validation in animal models. Its commitment to innovative and cooperative research positions it as a relevant center.

Oncostellae is a biotechnology company that develops small molecule drugs with innovative scaffolds. Its focus on drug discovery from conception to Phase I/II makes it a promising company in the development of new oncological therapies.

Lentistem is a medical biotechnology company that designs and produces therapeutic lentiviral vectors. Its goal is to develop the next generation of gene-based therapies, aspiring to be a global leader in gene delivery systems.

Angiotheragnostics focuses on developing new classes of drugs and biomarkers to prevent therapeutic cancer resistance. Its goal is to change the traditional trial-and-error model in oncology, seeking more effective treatments.

Fastbase Solutions develops diagnostic systems to accelerate the fight against diseases like cancer. Its contribution to early and precise diagnosis is fundamental for personalized and effective medicine, improving patient outcomes.

Oniria Therapeutics is evaluating the efficacy of an innovative drug in various types of cancer, stemming from research supported by the Spanish Association Against Cancer. It is part of pioneering initiatives seeking to accelerate the development of antitumor drugs.